Views
9 months ago

Anticoagulacion

Anticoagulación 65 16.

Anticoagulación 65 16. Gorelick PB. Carotid endarterectomy: where do we draw the line? Stroke 1999; 30: 1745-50. 17. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-62. 18. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-88. 19. Petersen P, Boysen G, Godtfredsen J, et al. Placebocontrolled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1: 175-79. 20. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990; 323: 1505-11. 21. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 84: 527-39. 22. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18: 349-55. 23. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327: 1406-12. 24. Halperin JL, Hart RG, Kronmal RA, et al. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-91. 25. McBride R, Stroke Prevention in Atrial Fibrillation Investigators. Adjusted dose warfarin versus low-intensity, fixed dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet 1996; 348: 633. 26. Van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: An individual patient meta-analysis. JAMA 2002; 288: 2441-2448. 27. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026. 28. Hart RG, Pearce LA, Koudstaal PJ. Transient ischemic attacks in patients with atrial fibrillation: implications for secondary prevention: the European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III trial. Stroke 2004; 35: 948-51. 29. Evans A, Perez I, Yu G, Kalra L. Secondary stroke prevention in atrial fibrillation: lessons from clinical practice. Stroke 2000; 31: 2106-11. 30. Wyse DG, Waldo AI, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. The AFFIRM Investigators: Atrial Fibrillation Follow-up Investigation of Rhythm Management. N Engl J Med 2002; 347 (23): 1825-33. 31. Van Gelder IC, Hagens VE, Bosker HA, et al. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347 (23): 1834-40. 32. Olsson SB. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III). Lancet 2003; 362: 1691-98. 33. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage: facts and hypotheses. Stroke 1995; 26: 1471-1477. 34. Mathiesen T, Benediktsdottir K, Johnsson H, Lindqvist M, von Holst H. Intracranial traumatic and non-traumatic haemorrhagic complications of warfarin treatment. Acta Neurol Scand 1995; 91: 208-214. 35. Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can Patients Be Anticoagulated After Intracerebral Hemorrhage? A Decision Analysis Stroke 2003; 34: 1710- 1716. 36. Loh VE, Martin ST, Sutton J, Chuan C, Chuan W, Jean D, Rouleau L, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997; 336: 251-7. 37. Cheng JW, Spinler SA. Should all patients with dilated cardiomyopathy receive chronic anticoagulation? Ann Pharmacother. 1994; 28 (5): 604-9. 38. Cannegieter SC, Rosendaal FR, Wintzen AR, Van Der Meer FJM, Vandenbrouke JP, Beriet B. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-7. 39. Mohr JP, Thompson JLP, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444-51. 40. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997; 42: 857-65. 41. Benesch CG, Chimowitz MI. Best treatment for intracranial arterial stenosis? 50 years of uncertainty. The WASID Investigators. Neurology 2000; 55: 465-6. 42. Lynn M, Chimowitz M, Howlett-Smith H, Frankel M, Hertzberg V, et al. Warfarin vs. Aspirin for Symptomatic Intracranial Stenosis: Subgroup Analyses From WASID. 30 th Stroke Conference. New Orleans; 2005. http://booksmedicos.blogspot.com

66 Anticoagulación en enfermedad cerebrovascular 43. Bertram M. Managing the therapeutic dilemma: patients with spontaneous intracerebral hemorrhage and urgent need for anticoagulation. J Neurol 2000; 247: 209-214. 44. Benamer HTS. Cerebral venous thrombosis: anticoagulants or thrombolyic therapy? J Neurol Neurosurg Psychiatry 2000; 69: 427-430. 45. Einhaupl KM. Heparin treatment in sinus venous thrombosis. Lancet 1991; 338: 597. 46. Bruijn S. Randomized, placebo-controlled trtial of anticoagulant treatment with low-molecular-weight heparin for cerebral venous thrombosis. Stroke 1999; 30: 484. 47. Biller J, Hingtgen WL, Adams HP, et al. Cervicocephalic arterial dissections: a ten year experience. Ann Neurol 1986; 43: 1234-38. 48. Bogousslavsky J, Despland PA, Regli F. Spontaneous carotid dissection with acute stroke. Arch Neurol 1987; 44: 137-140. 49. Crowther MA. Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-8. 50. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303-8. 51. Ruiz-Irastorza G, Khamashta MA, Hunt BJ, Escudero A, Cuadrado MJ, Hughes GR. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med 2002; 162: 1164-9. 52. Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolito melagatran: a mini review. Thromb Res 2003: 109: S9-S15. 53. Albers GW, Diener HC, Grind M, et al. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 1691-98) 54. Halperin JL, for the Executive Steering Committee on behalf of the SPORTIF V Investigators. Stroke Prevention Using the Oral Thrombin Inhibitor Ximelagatran in Patients with Nonvalvular Atrial Fibrillation V – SPORTIF V. Program and abstracts from the American Heart Association Scientific Sessions 2003; November 9-12, 2003; Orlando, Florida. Plenary Session VII: Late Breaking Clinical Trials. http://booksmedicos.blogspot.com

anticoagulacion oral y nuevos anticoagulantes orales. dabigatrán
Trombosis en el paciente oncológico - Sociedad Española de ...
uso de inhibidores de la bomba de
Temas Destacados XXIV Congreso Nacional de ... - Gador SA
avances012004.pdf - Asepeyo
COPYRIGHTED
ESTUDIO DEL PACIENTE DISLIPÉMICO
3er Consenso Uruguayo sobre Hipertensión Arterial - Sociedad ...
¿Qué necesitan nuestros pacientes para el alivio del dolor ... - Raffo
Más información - Sociedad Española de Oncología Médica
Antitrombóticas en Pacientes con Trauma - Reeme.arizona.edu
PROTOCOLOS - Sociedad Española de Medicina Interna
EACS Sociedad Clínica Europea del SIDA Guías clínicas - Versión 5 ...